About KBP BioSciences
KBP BioSciences is a company based in Princeton (United States) founded in 2007. KBP BioSciences has raised $76 million across 1 funding round from investors including SDIC, Efung Capital and Advantech Capital. KBP BioSciences operates in a competitive market with competitors including AskBio, Calliditas Therapeutics, Juvenescence, Insmed and Inotrem, among others.
- Headquarter Princeton, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$76 M (USD)
in 1 rounds
-
Latest Funding Round
$76 M (USD), Series A
Jan 05, 2018
-
Investors
SDIC
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of KBP BioSciences
KBP BioSciences has successfully raised a total of $76M through 1 strategic funding round. The most recent funding activity was a Series A round of $76 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in KBP BioSciences
KBP BioSciences has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include SDIC, Efung Capital and Advantech Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Efung Capital is focused on global biopharmaceutical investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
A venture capital firm focused on life sciences investments.
|
Locked | Locked | Locked |
Investor details for KBP BioSciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by KBP BioSciences
Investment portfolio details for KBP BioSciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - KBP BioSciences
Detailed financials for KBP BioSciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kbp Biosciences Comparisons
Peer comparison for KBP BioSciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of KBP BioSciences
KBP BioSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AskBio, Calliditas Therapeutics, Juvenescence, Insmed and Inotrem, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| Locked | Locked | Locked |
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health
|
|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
Detailed competitors of KBP BioSciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kbp Biosciences
Complete news archive for KBP BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KBP BioSciences
KBP BioSciences was founded in 2007 and raised its 1st funding round 11 years after it was founded.
KBP BioSciences is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
KBP BioSciences is a funded company, having raised a total of $76M across 1 funding round to date.
KBP Biosciences is developing medicine with a focus on following therapeutic areas: inflammatory and autoimmune diseases, major organ degeneration, and drug-resistant bacterial infection, as well as cancers and gastrointestinal disorders. Its drug pipeline inlcudes KBP-5074 (MR-specific antogonist) Chronic Kidney DiseaseHeart Failure (Phase 2); KBP-7072, a next generation tetracycline for multi-resistant bacterial infection (Phase 1). The company also have drug sin development for Asthma COPD; Fibrosis; Rheumatoid arthritis and Gram-Negative bacteria infections.
KBP BioSciences's top competitors include Juvenescence, AskBio and Calliditas Therapeutics.
KBP BioSciences has 10 investors. Key investors include SDIC, Efung Capital, Advantech Capital, Sangel Capital, and Ping An Ventures.